Home About Us Our Technology News + Media Investor Relations Contact Us
Company Press Releases Publications


Company Press Releases                                                                               Back

Recent CytoSorb® Case Reports Highlight its Use to Help Save the Lives of Critically-Ill Patients

Wednesday December 10, 2014

MONMOUTH JUNCTION, N.J., Dec. 10, 2014 /PRNewswire/ -- CytoSorbents Corporation (CTSOD), a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber to treat deadly inflammation in critically-ill patients, highlights recent treatment successes published in peer-reviewed journal articles.

Massive uncontrolled inflammation, driven by cytokine storm and other inflammatory toxins, can be deadly, particularly in patients with life-threatening illnesses such as septic shock, massive trauma, severe acute pancreatitis, liver failure, and many other inflammatory conditions. Without intervention, this deadly inflammation can rapidly lead to the failure of vital organs in the body, ultimately leading to death in many patients despite the use of modern life support technologies such as mechanical ventilation and dialysis. By filtering blood outside the body, CytoSorb® can reduce toxic levels of cytokines and other substances causing deadly inflammation, and now has been used to help stabilize and save the lives of many patients.

In the first published case report from India that can be downloaded from the December 2014 issue of the Indian Journal of Critical Care Medicine here, Basu, et al., describes a 36 year old woman who was admitted to the intensive care unit in Artemis Health Institute in Haryana, India with a severe urinary tract infection. Despite the use of broad spectrum antibiotics, her condition rapidly deteriorated, resulting in septic shock with kidney failure and the complete inability to make urine, lung failure requiring mechanical ventilation, and a life-threatening persistent drop in her blood pressure (shock) requiring maximum circulatory support with four different drugs called vasopressors. Her APACHE II score, a means of assessing the severity of illness, was 30 after 24 hours of admission, conferring a risk of death of approximately 75%conferring a risk of death of approximately 75%. Sixteen hours after admission, CytoSorb® therapy was started with continuous renal replacement therapy and continued for 3 days. After the initial 12 hours of therapy, the patient's blood pressure stabilized enabling the weaning off of nearly all vasopressors over the course of several days. Urine output increased, lung function improved, and the patient went on the recover.

In another recent published study from the December 2014 issue of the journal, Liver Transplantationrecent published study from the December 2014 issue of the journal, Liver Transplantation, Frimmel, et al., reports on the successful use of CytoSorb® therapy combined with single-pass albumin dialysis (SPAD) to rescue a 50-year woman admitted to the ICU with acute liver failure from complications of a disseminated herpes simplex virus (HSV) infection at the Rostock University Medical Center in Rostock, Germany. A poster of this case can be downloaded here. Although the patient required emergency liver transplantation, the patient rapidly became too unstable and developed severe compromise of multiple organ systems, including liver failure induced coma, severe clotting disorders, kidney failure with no urine output, acute lung injury, and shock. Despite the use of the anti-viral therapy acyclovir, and despite the use of traditional liver dialysis therapy (MARS), the patient continued to deteriorate, requiring increasing circulatory support with vasopressors, and developed a massive inflammatory response with an IL-6 cytokine concentration of ~81,000 pg/mL, far above normal (<10 pg/mL) and well above what is commonly seen in sepsis. CytoSorb® therapy was implemented with SPAD, and within 12 hours of treatment, the IL-6 level had fallen to ~17,200 pg/mL and the patient stabilized, allowing life-saving liver transplantation to occur on the 4th day in the ICU.

In the near future, we will be discussing more treatment successes reported at the recent Second Annual CytoSorb® Users Meeting in Hamburg, Germany, where more than 70 users from Germany, Austria, and Switzerland gathered to share their treatment experiences with CytoSorb®.

More exciting case report studies can be found on our website here.

About CytoSorbents Corporation

CytoSorbents Corporation is a critical care focused immunotherapy company using blood purification to control severe inflammation -- with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company's flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website: http://www.cytosorbents.com

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2014, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=1910667.

Please Click to Follow us on Facebook and Twitter

Company Contact
CytoSorbents, Inc
Dr. Phillip Chan
Chief Executive Officer
(732) 329-8885 ext. *823
Investor Contact

Amy Vogel
(732) 329-8885 ext. *825
Source: CytoSorbents Corporation

Home | Career Opportunities | Contact Us
© 2014 CytoSorbents Incorporated All Rights Reserved